MD1004Z - Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia - Google Patents
Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia Download PDFInfo
- Publication number
- MD1004Z MD1004Z MDS20150054A MDS20150054A MD1004Z MD 1004 Z MD1004 Z MD 1004Z MD S20150054 A MDS20150054 A MD S20150054A MD S20150054 A MDS20150054 A MD S20150054A MD 1004 Z MD1004 Z MD 1004Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- benign prostatic
- prostatic hyperplasia
- zinc oxide
- cold pressing
- Prior art date
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 16
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 13
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000011787 zinc oxide Substances 0.000 claims abstract description 12
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 10
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims abstract description 6
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims abstract description 6
- 239000010476 amaranth oil Substances 0.000 claims abstract description 6
- 235000000832 Ayote Nutrition 0.000 claims abstract description 4
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 4
- 240000001980 Cucurbita pepo Species 0.000 claims abstract description 4
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 4
- 239000003921 oil Substances 0.000 claims abstract description 4
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 4
- 210000000664 rectum Anatomy 0.000 claims abstract description 4
- 210000003932 urinary bladder Anatomy 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 210000002307 prostate Anatomy 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940072254 proscar Drugs 0.000 description 2
- 239000008171 pumpkin seed oil Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000021891 Micturition disease Diseases 0.000 description 1
- 108010009556 Vitaprost Proteins 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000026455 prostate symptom Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la urologie şi poate fi utilizată pentru tratamentul obstrucţiei infravezicale cauzate de hiperplazia benignă de prostată. The invention relates to medicine, in particular to urology and can be used for the treatment of infravesical obstruction caused by benign prostatic hyperplasia.
Obstrucţia infravezicală apare cel mai frecvent la vârstă înaintată şi în majoritatea cazurilor este cauzată de dezvoltarea unui proces hiperplazic în prostată. Hiperplazia benignă a prostatei (HBP) este una dintre cele mai răspândite maladii polietiologice la bărbaţii de vârstă înaintată şi senilă, care apare în urma proliferării zonei tranzitorii a prostatei şi a glandelor parauretrale, ce duce la obstrucţia căilor urinare inferioare. O dovadă în acest sens este faptul că potrivit datelor cercetărilor epidemiologice, HBP a fost depistată la 40% dintre bărbaţii cu vârste cuprinse între 50 şi 60 ani, la 50% dintre bărbaţii trecuţi de 60 ani şi la 90% - după 80 ani. Se consideră că majoritatea bărbaţilor cu vârste mai mari de 50 ani au unele sau altele simptome determinate de HBP, iar durata vieţii bărbaţilor în creştere contribuie la sporirea numărului bolnavilor care suferă de această maladie. Clinic această maladie se manifestă prin diferite simptome legate de dereglarea pasajului urinei prin căile urinare inferioare. Cauzele tulburării micţiunii sunt obstrucţia infravezicală şi slăbirea funcţiei detrusorului. Obstrucţia are la bază creşterea în dimensiuni a prostatei cu îngustarea treptată a lumenului uretrei (componenta mecanică) şi hipertonusul fibrelor musculare netede ale prostatei şi uretrei posterioare (componenta dinamică). Tratamentul hiperplaziei benigne a prostatei rămâne până în prezent o problemă actuală. Pe parcursul ultimilor 20 ani a apărut posibilitatea de a trata bolnavii la stadii incipiente ale acestei maladii cu preparate medicamentoase corespunzătoare. Infravesical obstruction occurs most frequently in old age and in most cases is caused by the development of a hyperplastic process in the prostate. Benign prostatic hyperplasia (BPH) is one of the most common polyetiological diseases in old and senile men, which occurs as a result of proliferation of the transitional zone of the prostate and paraurethral glands, which leads to obstruction of the lower urinary tract. Evidence in this regard is the fact that according to epidemiological research data, BPH was detected in 40% of men aged between 50 and 60 years, in 50% of men over 60 years and in 90% - after 80 years. It is believed that most men over 50 years have some or other symptoms caused by BPH, and the increasing life expectancy of men contributes to the increase in the number of patients suffering from this disease. Clinically, this disease manifests itself through various symptoms related to the disorder of the passage of urine through the lower urinary tract. The causes of micturition disorder are infravesical obstruction and weakening of the detrusor function. The obstruction is based on the increase in the size of the prostate with the gradual narrowing of the urethral lumen (mechanical component) and hypertonicity of the smooth muscle fibers of the prostate and posterior urethra (dynamic component). The treatment of benign prostatic hyperplasia remains a current problem to this day. Over the past 20 years, the possibility of treating patients in the early stages of this disease with appropriate medicinal preparations has emerged.
Dintre metodele existente de terapie medicamentoasă a obstrucţiei infravezicale, provocată de hiperplazia benignă a prostatei, cea mai eficientă constă în administrarea remediului medicamentos „Vitaprost Forte”, sub formă de supozitorii rectale, în doză de 100 mg, o dată în zi, timp de 60 zile. Dintre 30 de pacienţi care au fost supuşi tratamentului un efect pozitiv înalt s-a observat la 8 (26,7%), efect satisfăcător s-a observat la 12 (40%) şi slab pozitiv la 10 (33,3%) din bolnavi [1]. Among the existing methods of drug therapy of infravesical obstruction caused by benign prostatic hyperplasia, the most effective is the administration of the drug "Vitaprost Forte", in the form of rectal suppositories, in a dose of 100 mg, once a day, for 60 days. Among 30 patients who underwent treatment, a high positive effect was observed in 8 (26.7%), a satisfactory effect was observed in 12 (40%) and a weak positive effect in 10 (33.3%) of the patients [1].
Dezavantajele acestei metode constau în aceea că manifestă un efect de scurtă durată 2,5…3 luni după tratament şi se aplică la un contingent limitat de bolnavi cu HBP în stadiul I. Cele mai radicale continuă să fie considerate doar metodele chirurgicale, care includ adenomectomia deschisă şi rezecţia transuretrală a HBP, iar în tratamentul hiperplaziei benigne a prostatei de dimensiuni mari, metoda chirurgicală principală este adenomectomia transvezicală transversală. The disadvantages of this method are that it has a short-term effect 2.5…3 months after treatment and is applied to a limited contingent of patients with stage I BPH. Only surgical methods continue to be considered the most radical, which include open adenomectomy and transurethral resection of BPH, and in the treatment of large benign prostatic hyperplasia, the main surgical method is transverse transvesical adenomectomy.
Problema pe care o soluţionează invenţia constă în sporirea eficienţei tratamentului medicamentos la pacienţii cu obstrucţia infravezicală provocată de hiperplazia benignă a prostatei, deoarece majoritatea bărbaţilor care suferă de această maladie au o vârstă înaintată, nu la toţi este posibil să se efectueze intervenţii chirurgicale din cauza maladiilor cronice persistente. The problem solved by the invention consists in increasing the efficiency of drug treatment in patients with infravesical obstruction caused by benign prostatic hyperplasia, since most men suffering from this disease are of advanced age, not all of them are able to undergo surgical interventions due to persistent chronic diseases.
Esenţa invenţiei constă în aceea că o dată în zi, per rectum, prin microclisme se administrează în volum de 30 ml un amestec ozonat pe bază de ulei de dovleac, obţinut prin presare la rece, ce conţine 5 mg de nanoparticule de oxid de zinc şi argint, luate în raport de 9:1, cu concentraţia ozonului de 9000 µg/l şi 5 mg de un inhibitor al 5α reductazei, apoi după 2,5 ore se goleşte complet vezica urinară şi se instilează 150 ml de un amestec ozonat, pe bază de ulei de amarant, obţinut prin presare la rece cu concentraţia ozonului de 10000 µg/l, ce conţine 5 mg de nanoparticule de oxid de zinc şi argint, luate în raport de 9:1, seria de tratament constituie 40 zile. The essence of the invention consists in that once a day, per rectum, through microenemas, an ozonated mixture based on pumpkin oil, obtained by cold pressing, is administered in a volume of 30 ml, containing 5 mg of zinc oxide and silver nanoparticles, taken in a ratio of 9:1, with an ozone concentration of 9000 µg/l and 5 mg of a 5α reductase inhibitor, then after 2.5 hours, the urinary bladder is completely emptied and 150 ml of an ozonated mixture based on amaranth oil, obtained by cold pressing with an ozone concentration of 10000 µg/l, containing 5 mg of zinc oxide and silver nanoparticles, taken in a ratio of 9:1, is instilled, the treatment series is 40 days.
Rezultatul invenţiei constă în evidenţierea unei metode de tratament care manifestă o eficacitate sporită faţă de cea mai apropiată soluţie şi prin aceasta se evită o intervenţie chirurgicală, este simplă în executare şi poate fi aplicată la pacienţii de orice vârstă. The result of the invention consists in highlighting a treatment method that exhibits increased effectiveness compared to the closest solution and thereby avoids surgical intervention, is simple to perform and can be applied to patients of any age.
Rezultatele tratării pacienţilor cu obstrucţie infravezicală provocată de hiperplazia benignă de prostată conform celei mai apropiate soluţii şi conform soluţiei revendicate Results of treating patients with infravesical obstruction caused by benign prostatic hyperplasia according to the closest solution and according to the claimed solution
Criteriile de apreciere a rezultatelor tratamentului La începutul tratamentului Peste 30 zile Peste 40 zile Peste 60 zile Suma de puncte conform scării IPSS (International Prostate Symptom Score), valori absolute 13,9±2,1 14,1±1,5 11,8±2,3 8,8±2,1 6,8±1,1 9,7±1,7 6,0±1,5 Calitatea vieţii conform scării QOLS (Quality of Life Scale), valori absolute 3,8±0,4 3,5±0,7 3,0±0,7 2,7,0±0,2 2,1,0±0,2 2,6±0,5 1,5±0,3 Viteza maximă a urinei Qmax, ml/s 9,3±0,9 9,8±1,2 10,5±0,6 10,8±0,6 13,0±0,2 12,9±0,4 15,0±0,1 Cantitatea urinei restante, ml 65,5±12,9 60,1±10,3 42,4±10,5 35,6±8,5 30,2±2,5 33,8±9,1 20,5±1,5 Volumul prostatei, cm3 48,5±5,5 51,5±3,5 47,8±6,1 48,8±1,2 45,8±0,7 44,2±3,7 40,1±0,3Criteria for assessing treatment results At the beginning of treatment Over 30 days Over 40 days Over 60 days Sum of points according to the IPSS scale (International Prostate Symptom Score), absolute values 13.9±2.1 14.1±1.5 11.8±2.3 8.8±2.1 6.8±1.1 9.7±1.7 6.0±1.5 Quality of life according to the QOLS scale (Quality of Life Scale), absolute values 3.8±0.4 3.5±0.7 3.0±0.7 2.7.0±0.2 2.1.0±0.2 2.6±0.5 1.5±0.3 Maximum urine velocity Qmax, ml/s 9.3±0.9 9.8±1.2 10.5±0.6 10.8±0.6 13.0±0.2 12.9±0.4 15.0±0.1 Amount of remaining urine, ml 65.5±12.9 60.1±10.3 42.4±10.5 35.6±8.5 30.2±2.5 33.8±9.1 20.5±1.5 Prostate volume, cm3 48.5±5.5 51.5±3.5 47.8±6.1 48.8±1.2 45.8±0.7 44.2±3.7 40.1±0.3
Conform datelor din tabelul de mai sus, durata tratamentului este mai mică în comparaţie cu cea mai apropiată soluţie, deoarece deja la a 40-a zi rezultatele sunt superioare faţă de cea mai apropiată soluţie, unde abia la a 60-a zi se obţine un efect pozitiv. Rezultatul tehnic se datorează selectării reuşite a componentelor, precum şi combinării lor atât calitative cât şi cantitative cu nanoparticule de oxid de zinc şi argint, dar şi datorită modului de administrare reuşit ales. According to the data in the table above, the duration of treatment is shorter compared to the closest solution, because already on the 40th day the results are superior to the closest solution, where a positive effect is achieved only on the 60th day. The technical result is due to the successful selection of components, as well as their qualitative and quantitative combination with zinc oxide and silver nanoparticles, but also due to the successful administration method chosen.
Metoda se realizează în felul următor: o dată în zi, per rectum, prin microclisme se administrează în volum de 30 ml un amestec ozonat pe bază de ulei de dovleac, obţinut prin presare la rece, ce conţine 5 mg de nanoparticule de oxid de zinc şi argint, luate în raport de 9:1, cu concentraţia ozonului de 9000 µg/l şi 5 mg de un inhibitor al 5α reductazei, apoi după 2,5 ore se goleşte complet vezica urinară şi se instilează 150 ml de un amestec ozonat, pe bază de ulei de amarant, obţinut prin presare la rece cu concentraţia ozonului de 10000 µg/l, ce conţine 5 mg de nanoparticule de oxid de zinc şi argint, luate în raport de 9:1, seria de tratament constituie 40 zile. The method is performed as follows: once a day, per rectum, through microenemas, an ozonated mixture based on pumpkin oil, obtained by cold pressing, is administered in a volume of 30 ml, containing 5 mg of zinc oxide and silver nanoparticles, taken in a ratio of 9:1, with an ozone concentration of 9000 µg/l and 5 mg of a 5α reductase inhibitor, then after 2.5 hours, the bladder is completely emptied and 150 ml of an ozonated mixture based on amaranth oil, obtained by cold pressing with an ozone concentration of 10000 µg/l, containing 5 mg of zinc oxide and silver nanoparticles, taken in a ratio of 9:1, is instilled, the treatment series is 40 days.
Uleiul de dovleac, uleiul de amarant, obţinute prin presare la rece, şi inhibitorul 5α reductazei (Proscar) pot fi procurate în reţeaua de comerţ a Republicii Moldova, iar nanoparticulele de oxid de zinc şi argint pot fi uşor procurate în reţelele de comerţ ale Federaţiei Ruse din octombrie 2012. Nanoparticulele sunt destinate pentru transportarea eficientă a substanţelor biologic active în locul ţintă al patologiei. O particularitate semnificativă a nanoparticulelor este că ele pătrund în membrana celulară şi pot precipita la suprafaţa sferică mai multe celule de substanţe biologic active, medicamente, polimere etc. Aceste caracteristici au stat la baza aplicării nanoparticulelor în scopul dezintoxicării şi în calitate de conductor. În aşa fel, în anul 2000 nanoparticulele au fost utilizate la pacienţii oncologici care au fost supuşi radio- şi chimioterapiei. Pumpkin seed oil, amaranth oil, obtained by cold pressing, and 5α reductase inhibitor (Proscar) can be purchased in the retail network of the Republic of Moldova, and zinc oxide and silver nanoparticles can be easily purchased in the retail networks of the Russian Federation since October 2012. Nanoparticles are intended for the efficient transport of biologically active substances to the target site of pathology. A significant feature of nanoparticles is that they penetrate the cell membrane and can precipitate on the spherical surface several cells of biologically active substances, drugs, polymers, etc. These characteristics formed the basis for the application of nanoparticles for the purpose of detoxification and as a conductor. Thus, in 2000 nanoparticles were used in oncological patients who underwent radio- and chemotherapy.
Amestecul pentru utilizare în microclisme se obţine în felul următor: într-un vas de 15 l se toarnă 10 l de ulei de dovleac, obţinut prin presare la rece, apoi se adaugă 5 mg de praf de nanoparticule de oxid de zinc şi argint, luate în raport de 9:1, şi 5 mg de un inhibitor al 5α reductazei (Proscar), după care soluţia se malaxează până la omogenizare şi se ozonează până la conţinutul de ozon de 9000 µg/l. The mixture for use in microenemas is obtained as follows: in a 15 l vessel, pour 10 l of pumpkin seed oil, obtained by cold pressing, then add 5 mg of zinc oxide and silver nanoparticle powder, taken in a ratio of 9:1, and 5 mg of a 5α reductase inhibitor (Proscar), after which the solution is kneaded until homogenized and ozonized to an ozone content of 9000 µg/l.
Amestecul pentru instilarea vezicii urinare se obţine în felul următor: într-un vas de 15 l se toarnă 10 l de ulei de amarant obţinut prin presare la rece, apoi se adaugă 5 mg de praf de nanoparticule de oxid de zinc şi argint luate în raport de 9:1, după care soluţia se malaxează până la omogenizare şi se ozonează până la conţinutul de ozon de 10000 µg/l. The mixture for instillation of the urinary bladder is obtained as follows: in a 15 l vessel, pour 10 l of amaranth oil obtained by cold pressing, then add 5 mg of zinc oxide and silver nanoparticle powder taken in a ratio of 9:1, after which the solution is kneaded until homogenized and ozonized to an ozone content of 10,000 µg/l.
Exemplu concret de realizare Concrete example of achievement
Pacientul A., 56 ani, a fost internat în secţia urologie cu acuze la micţiune întreruptă care se efectuează prin depunerea de efort, senzaţia de golire insuficientă a vezicii urinare, micţiuni nocturne de 5 ori pe noapte şi odată în decursul zilei micţiuni involuntare, a fost determinată suma de puncte conform scării IPSS - 14; Calitatea vieţii conform scării QOLS - 4; Viteza maximă a urinei Qmax - 10; Cantitatea urinei restante - 60 ml şi volumul prostatei - 52 cm3, s-a stabilit diagnosticul clinic de obstrucţie infravezicală provocată de hiperplazia benignă a prostatei asociată cu hipertonie arterială de gr. II. Pacientul a urmat un tratament conform metodei revendicate, peste 40 zile s-au determinat următorii indici: micţiunea fără efort şi neîntreruptă, a dispărut senzaţia de golire insuficientă a vezicii urinare, micţiunile nocturne s-au redus la 2, iar cele involuntare au dispărut, IPSS - 7; QOLS - 3; Viteza maximă a urinei Qmax - 13; Cantitatea urinei restante - 30 ml şi volumul prostatei - 45 cm3. Patient A., 56 years old, was admitted to the urology department with complaints of interrupted urination that occurs with effort, the feeling of insufficient emptying of the bladder, nocturnal urination 5 times a night and once during the day involuntary urination, the sum of points according to the IPSS scale was determined - 14; Quality of life according to the QOLS scale - 4; Maximum urine velocity Qmax - 10; Amount of remaining urine - 60 ml and prostate volume - 52 cm3, the clinical diagnosis of infravesical obstruction caused by benign prostatic hyperplasia associated with grade II arterial hypertension was established. The patient underwent treatment according to the claimed method, over 40 days the following indices were determined: effortless and uninterrupted urination, the feeling of insufficient bladder emptying disappeared, nocturnal urinations were reduced to 2, and involuntary ones disappeared, IPSS - 7; QOLS - 3; Maximum urine velocity Qmax - 13; Amount of remaining urine - 30 ml and prostate volume - 45 cm3.
Conform metodei revendicate au fost trataţi 203 pacienţi care au fost monitorizaţi pe parcursul a 2 ani, perioada de remisie a constituit 7 luni în comparaţie cu cea mai apropiată soluţie, în care a fost de 3 luni. According to the claimed method, 203 patients were treated and monitored for 2 years, the remission period was 7 months compared to the closest solution, in which it was 3 months.
1. Ткачук В.Н., Ткачук И.Н. Эффективность препарата Витапрост форте у больных с доброкачественной гиперплазией предстательной железы. Санкт-Петерсбург, Государственный медицинский университет, 2014 <URL: http://medi.ru/doc/g2401204.htm> 1. Tkachuk V.N., Tkachuk I.N. Effectiveness of the drug Vitaprost forte in patients with benign prostate hyperplasia. Saint Petersburg, State Medical University, 2014 <URL: http://medi.ru/doc/g2401204.htm>
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150054A MD1004Z (en) | 2015-04-10 | 2015-04-10 | Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150054A MD1004Z (en) | 2015-04-10 | 2015-04-10 | Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1004Y MD1004Y (en) | 2016-02-29 |
| MD1004Z true MD1004Z (en) | 2016-09-30 |
Family
ID=55447198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20150054A MD1004Z (en) | 2015-04-10 | 2015-04-10 | Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1004Z (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109528806B (en) * | 2018-12-19 | 2021-08-06 | 刘东波 | Sterol composition in pumpkin seed oil and its application and medicine for treating benign prostatic hyperplasia |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1146066A1 (en) * | 1983-06-17 | 1985-03-23 | Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии | Method of treatment of patients ill with prostate adenoma |
| SU1159578A1 (en) * | 1981-06-22 | 1985-06-07 | Запорожский государственный институт усовершенствования врачей им.М.Горького | Method of treatment of prostate adenoma |
| SU1163859A1 (en) * | 1983-12-23 | 1985-06-30 | Министерство Здравоохранения Латвсср | Method of testing chronic prosthatite |
| MD482F1 (en) * | 1995-12-29 | 1996-10-31 | Svetskii & Co Fa | Continuous acted mixer |
| UA63883C2 (en) * | 1997-10-30 | 2004-02-16 | Петрушевський Іван Іванович | Massaging device for preventing and treating adenoma of prostate |
| MD2788G2 (en) * | 2004-07-28 | 2006-01-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Entomologic anti-inflammatory and antioxidant preparation |
| MD2952G2 (en) * | 2005-07-26 | 2006-08-31 | Валериу РУДИК | Medicinal remedy in the form of suppositories for prostatitis treatment |
| UA32566U (en) * | 2007-12-06 | 2008-05-26 | Харьковская Медицинская Академия Последипломного Образования | Method for treatment of patients suffering from adenoma of prostate and chronic prostatitis |
| MD3426G2 (en) * | 2007-02-02 | 2008-10-31 | Виктор БОБУ | Urological draining device |
| MD3804G2 (en) * | 2008-07-08 | 2009-09-30 | Виктор БОБУ | Method for endourethral drainage in urological lower floor organs operations |
| MD4025C2 (en) * | 2009-08-25 | 2010-10-31 | Владимир КАРАУШ | Remedy for treating prostatitis and prostate hyperplasia |
| RU2010110513A (en) * | 2010-03-22 | 2011-09-27 | Общество с ограниченной ответственностью "ЭкоБиоФарм" (RU) | METHOD FOR DIAGNOSTIC OF ONCOLOGICAL DISEASES OF THE PROSTATURE ON THE BASIS OF Acylcarnitine And Arachidonoyl Amine |
| RU2011124639A (en) * | 2011-06-16 | 2012-12-27 | Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" | METHOD FOR TREATING PURULO-SEPTIC COMPLICATIONS IN PROSTATE Adenoma |
| MD4296C1 (en) * | 2012-12-28 | 2015-03-31 | Вячеслав ЧУХРИЙ | Preparation from Tenebrio molitor larvae with antioxidant activity, process for its preparation and pharmaceutical product on its base |
-
2015
- 2015-04-10 MD MDS20150054A patent/MD1004Z/en not_active IP Right Cessation
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1159578A1 (en) * | 1981-06-22 | 1985-06-07 | Запорожский государственный институт усовершенствования врачей им.М.Горького | Method of treatment of prostate adenoma |
| SU1146066A1 (en) * | 1983-06-17 | 1985-03-23 | Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии | Method of treatment of patients ill with prostate adenoma |
| SU1163859A1 (en) * | 1983-12-23 | 1985-06-30 | Министерство Здравоохранения Латвсср | Method of testing chronic prosthatite |
| MD482F1 (en) * | 1995-12-29 | 1996-10-31 | Svetskii & Co Fa | Continuous acted mixer |
| UA63883C2 (en) * | 1997-10-30 | 2004-02-16 | Петрушевський Іван Іванович | Massaging device for preventing and treating adenoma of prostate |
| MD2788G2 (en) * | 2004-07-28 | 2006-01-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Entomologic anti-inflammatory and antioxidant preparation |
| MD2952G2 (en) * | 2005-07-26 | 2006-08-31 | Валериу РУДИК | Medicinal remedy in the form of suppositories for prostatitis treatment |
| MD3426G2 (en) * | 2007-02-02 | 2008-10-31 | Виктор БОБУ | Urological draining device |
| UA32566U (en) * | 2007-12-06 | 2008-05-26 | Харьковская Медицинская Академия Последипломного Образования | Method for treatment of patients suffering from adenoma of prostate and chronic prostatitis |
| MD3804G2 (en) * | 2008-07-08 | 2009-09-30 | Виктор БОБУ | Method for endourethral drainage in urological lower floor organs operations |
| MD4025C2 (en) * | 2009-08-25 | 2010-10-31 | Владимир КАРАУШ | Remedy for treating prostatitis and prostate hyperplasia |
| RU2010110513A (en) * | 2010-03-22 | 2011-09-27 | Общество с ограниченной ответственностью "ЭкоБиоФарм" (RU) | METHOD FOR DIAGNOSTIC OF ONCOLOGICAL DISEASES OF THE PROSTATURE ON THE BASIS OF Acylcarnitine And Arachidonoyl Amine |
| RU2011124639A (en) * | 2011-06-16 | 2012-12-27 | Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" | METHOD FOR TREATING PURULO-SEPTIC COMPLICATIONS IN PROSTATE Adenoma |
| RU2481847C2 (en) * | 2011-06-16 | 2013-05-20 | Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" | Method of treating suppurative septic complications of prostate adenoma |
| MD4296C1 (en) * | 2012-12-28 | 2015-03-31 | Вячеслав ЧУХРИЙ | Preparation from Tenebrio molitor larvae with antioxidant activity, process for its preparation and pharmaceutical product on its base |
Non-Patent Citations (1)
| Title |
|---|
| Ткачук В.Н., Ткачук И.Н. Эффективность препарата Витапрост форте у больных с доброкачественной гиперплазией предстательной железы. Санкт-Петерсбург, Государственный медицинский университет, 2014 <URL: http://medi.ru/doc/g2401204.htm> * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD1004Y (en) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haybar et al. | Endothelial cells: from dysfunction mechanism to pharmacological effect in cardiovascular disease | |
| Gibson et al. | New horizons: urinary incontinence in older people | |
| Yang et al. | Porous Se@ SiO2 nanosphere-coated catheter accelerates prostatic urethra wound healing by modulating macrophage polarization through reactive oxygen species-NF-κB pathway inhibition | |
| JP4588325B2 (en) | How to treat ileus | |
| Troidl et al. | Effects of endogenous nitric oxide and of DETA NONOate in arteriogenesis | |
| Gong et al. | Mechanism of miR-132-3p promoting neuroinflammation and dopaminergic neurodegeneration in Parkinson’s disease | |
| Veerasarn et al. | A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis | |
| Watanabe et al. | Suppression of abdominal aortic aneurysm formation by inhibition of prolyl hydroxylase domain protein through attenuation of inflammation and extracellular matrix disruption | |
| Liang et al. | Jmjd3/IRF4 axis aggravates myeloid fibroblast activation and m2 macrophage to myofibroblast transition in renal fibrosis | |
| Veerasarn et al. | Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial | |
| Park et al. | Synergistic activity of N-hydroxy-7-(2-naphthylthio) heptanomide and sorafenib against cancer stem cells, anaplastic thyroid cancer | |
| Qiao et al. | Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: A single center, randomized control study | |
| Challa et al. | Therapeutic efficacy of matrix metalloproteinase-12 suppression on neurological recovery after ischemic stroke: optimal treatment timing and duration | |
| Zou et al. | Rofecoxib attenuates the pathogenesis of amyotrophic lateral sclerosis by alleviating cyclooxygenase-2-mediated mechanisms | |
| Hannick et al. | Canadian Urological Association best practice report: pediatric hemorrhagic cystitis | |
| Ozdemir et al. | Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms | |
| Zhang et al. | Diclofenac sodium nanomedicine results in pain-relief and differential expression of the RNA transcriptome in the spinal cord of SNI rats | |
| Huang et al. | Fucosterol ameliorates depressive-like behaviours by suppressing microglial activation and neuroinflammation via inhibition the MAPK/ERK1/2 signaling pathway | |
| MD1004Z (en) | Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia | |
| Chang et al. | Preconditioning of surgical pedicle flaps with DNA plasmid expressing hypoxia-inducible factor-1α (HIF-1α) promotes tissue viability | |
| Tugcu et al. | Effectiveness of acupuncture in patients with category IIIB chronic pelvic pain syndrome: a report of 97 patients | |
| Matsui et al. | Increased level of tumor necrosis factor-alpha (TNF-α) leads to downregulation of nitrergic neurons following bilateral cavernous nerve injury and modulates penile smooth tone | |
| Yue et al. | IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells | |
| Mansouri | Eosinophilic cystitis and interstitial cystitis: may allergy be the reason | |
| Hu et al. | Therapeutic potential of meloxicam in ameliorating sepsis-induced renal injury through the PI3K/AKT pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |